I
Ingersoll Rand Inc.
IR · Industrials
Q4 FY2025
Earning ended Dec 31, 2025Report generated Mar 10, 2026
Factory Floor Equipment Company Quietly Assembling a Life-Science Tools Franchise
The consensus reads Ingersoll Rand as a cyclical industrial levered to factory-floor capex cycles; what it misses is that Precision and Science Technologies is assembling a fundamentally different franchise — one where pumps are FDA-qualified, switching involves regulatory recertification, and competitive dynamics resemble analytical instrumentation far more than air compression.
Flowly Score
Apr 16 Close
-2%$83.65
Fair Value
$82.00
54
Averageat $83.65
Business Strength7/10
IRX is a genuine operating system, not marketing wallpaper — the five-year margin trajectory is the empirical proof. The moat is real and directionally widening, but ROIC barely clearing cost of capital means the acquisition machine hasn't yet demonstrated it earns premium returns on aggregate deployed capital.
Financial Resilience7/10
OCF consistently and materially outpacing reported net income is one of the cleaner cash quality signals in industrials — the business generates more real cash than GAAP admits, and the CapEx burden is almost insultingly small for a company operating at this scale and complexity. Piotroski at 6 and Altman Z comfortably above the distress zone confirm structural balance sheet health.
Growth & Trajectory6/10
Recurring revenue more than doubling in two years and life sciences showing mid-teens order growth are the genuine bright spots, but management explicitly refusing to embed market recovery into 2026 guidance — and guiding Q1 flat-to-down organically — signals real near-term momentum uncertainty. The PST mix shift toward higher-quality end markets is the structural tailwind that matters most over five years.
Valuation4/10at $86.66
The neutral DCF scenario anchors materially below where shares trade today, and only a sustained FCF growth trajectory implying significant acceleration from current pace produces a fair value above the current price — that asks buyers to treat the optimistic scenario as the base case. The FCF yield provides partial comfort but insufficient margin of safety given the uncertainty in the earnings recovery timeline.
Risk5/10
Atlas Copco running the same strategic playbook with arguably a longer IoT head start is the most concrete and present competitive threat, and digital disintermediation of the aftermarket stream — the highest-quality cash flow in the portfolio — is the risk the bull case structurally underweights. The 40% aftermarket revenue base and geographic diversification are genuine buffers, but tariff headwinds, China deceleration, and a combined CEO/Chairman role amplify downside scenarios.
The investment case is a quality compounder priced at a multiple that requires the optimistic scenario to function as the base case. The operating system has demonstrably improved margins across the portfolio over five years, the aftermarket flywheel is compounding, and recurring revenue has grown dramatically. But ROIC barely clearing cost of capital is the honest summary of where this franchise sits today: a business on a trajectory toward excellent returns, not yet at one that justifies the current multiple without assuming meaningful reacceleration in cash earnings per share. The PST segment is the single variable most worth watching. If it continues scaling as a share of total revenue — bringing FDA-grade switching costs, lab-validated customer relationships, and life-science growth dynamics — the market is systematically applying the wrong peer group multiple to the consolidated business. Management's 2026 guidance already signals PST margin expanding nearly three hundred basis points while ITS stays flat; that divergence is the strategic story hiding inside the headline numbers, and it compounds quietly whether or not the industrial cycle cooperates. The single most specific risk is not the macro cycle or China — it is a well-capitalized rival deliberately constructing a connected equipment ecosystem that could route aftermarket service relationships through digital platforms rather than proprietary service channels. The aftermarket stream is the crown jewel of the moat. If self-diagnosing equipment normalizes third-party service platforms industry-wide, this franchise's most durable competitive advantage erodes without any single dramatic inflection point to announce it.